The role of CDKN2A/B deletions in pediatric acute lymphoblastic leukemia

References

• Esparza SD, Sakamoto KM. Topics in pediatric leukemia—acute lymphoblastic leukemia. MedGenMed 2005;7(1):23.
   PubMedGoogle Scholar
• Harrison CJ. Cytogenetics of paediatric and adolescent acute lymphoblastic leukaemia. Br J Haematol 2009;144:147–156.
   PubMed Web of Science ®Google Scholar
• Beroukhim R, Mermel CH, Porter D, et al. The landscape of somatic copy-number alteration across human cancers. Nature 2010;463:899–905.
   PubMed Web of Science ®Google Scholar
• Chapman EJ, Harnden P, Chambers P, Johnston C, Knowles MA. Comprehensive analysis of CDKN2A status in microdissected urothelial cell carcinoma reveals potential haploinsufficiency, a high frequency of homozygous co-deletion and associations with clinical phenotype. Clin Cancer Res 2005;11:5740–5747.
   PubMed Web of Science ®Google Scholar
• Carter TL, Watt PM, Kumar R, et al. Hemizygous p16(INK4A) deletion in pediatric acute lymphoblastic leukemia predicts independent risk of relapse. Blood 2001;97:572–574.
   PubMed Web of Science ®Google Scholar
• Dalle JH, Fournier M, Nelken B, et al. p16INK4a immunocytochemical analysis is an independent prognostic factor in childhood acute lymphoblastic leukemia. Blood 2002;99:2620–2623.
   PubMed Web of Science ®Google Scholar
• Zhou M, Gu L, Yeager AM, Findley HW. Incidence and clinical significance of CDKN2/MTS1/P16ink4A and MTS2/P15ink4B gene deletions in childhood acute lymphoblastic leukemia. Pediatr Hematol Oncol 1997;14:141–150.
   PubMed Web of Science ®Google Scholar
• Kees UR, Burton PR, Lu C, Baker DL. Homozygous deletion of the p16/MTS1 gene in pediatric acute lymphoblastic leukemia is associated with unfavorable clinical outcome. Blood 1997;89:4161–4166.
   PubMed Web of Science ®Google Scholar
• Mirebeau D, Acquaviva C, Suciu S, et al. The prognostic significance of CDKN2A, CDKN2B and MTAP inactivation in B-lineage acute lymphoblastic leukemia of childhood: results of the EORTC studies 58881 and 58951. Haematologica 2006;91:881–885.
   PubMed Web of Science ®Google Scholar
• van Zutven LJ, van Drunen E, de Bont JM, et al. CDKN2 deletions have no prognostic value in childhood precursor-B acute lymphoblastic leukaemia. Leukemia 2005;19(7):1281–1284.
   PubMed Web of Science ®Google Scholar
• Ramakers-van Woerden NL, Pieters R. In vitro drug resistance and prognostic impact of p16INK4A/P15INK4B deletions in childhood T-cell acute lymphoblastic leukaemia. Br J Haematol 2001;112(3):680–690.
   PubMed Web of Science ®Google Scholar
• Xiao XZ, Xu N, Zhang JF, et al. Comparison of clinical implications of p16 deletion in childhood and adult B-lineage acute lymphoblastic leukemia. Zhonghua Xue Ye Xue Za Zhi 2013 May;34(5):389–394.
   PubMedGoogle Scholar
• Karrman K, Castor A, Behrendtz M, et al. Deep sequencing and SNP array analyses of pediatric T-cell acute lymphoblastic leukemia reveal NOTCH1mutations in minor subclones and a high incidence of uniparental isodisomies affecting CDKN2A. J Hematol Oncol. 2015;8:42.
   PubMed Web of Science ®Google Scholar
• Sherr CJ. Cancer cell cycles. Science 1996;274:1672–1677.
   PubMed Web of Science ®Google Scholar
• Stott FJ, Bates S, James MC, et al. The alternative product from the human CDKN2A locus, p14ARF, participates in a regulatory feedback loop with p53 and MDM2. EMBO J 1998;17:5001–5014.
   PubMed Web of Science ®Google Scholar
• Hannon GJ, Beach D. p15INK4B is a potential effector of TGFbeta-induced cell cycle arrest. Nature 1994;371:257–261.
   PubMedGoogle Scholar
• Krug U, Ganser A, Koeffler HP. Tumor suppressor genes in normal and malignant hematopoiesis. Oncogene 2002;21(21):3475–3495.
   PubMed Web of Science ®Google Scholar
• Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999;13:1501–1512.
   PubMed Web of Science ®Google Scholar
• Huschtscha LI, Reddel RR. p16INK4a and the control of cellular proliferative life span. Carcinogenesis 1999;20:921–926.
   PubMed Web of Science ®Google Scholar
• Taylor WR, Stark GR. Regulation of the G2/M transition by p53. Oncogene 2001;20:1803–1815.
   PubMedGoogle Scholar
• Bartek J, Lukas J. Pathways governing G1/S transition and their response to DNA damage. FEBS Lett 2001;490:117–122.
   PubMed Web of Science ®Google Scholar
• Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000;408:307–310.
   PubMed Web of Science ®Google Scholar
• Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992;69:1237–1245.
   PubMed Web of Science ®Google Scholar
• Othman MA, Melo JB, Carreira IM, et al. High rates of submicroscopic aberrations in karyotypically normal acute lymphoblastic leukemia. Mol Cytogenet 2015;8:45.
   PubMed Web of Science ®Google Scholar
• Sulong S, Moorman AV, Irving JA, et al. A comprehensive analysis of the CDKN2A gene in childhood acute lymphoblastic leukemia reveals genomic deletion, copy number neutral loss of heterozygosity, and association with specific cytogenetic subgroups. Blood 2009;113:100–107.
   PubMed Web of Science ®Google Scholar
• Ohnishi H, Kawamura M, Ida K, et al. Homozygous deletions of p16/MTS1 gene are frequent but mutations are infrequent in childhood T-cell acute lymphoblastic leukemia. Blood 1995;86:1269–1275.
   PubMed Web of Science ®Google Scholar
• Bertin R, Acquaviva C, Mirebeau D, GuidalGiroux C, Vilmer E, Cave H. CDKN2A, CDKN2B, and MTAP gene dosage permits precise characterization of mono- and bi-allelic 9p21 deletions in childhood acute lymphoblastic leukemia. Genes Chromosomes Cancer 2003;37:44–57.
   PubMed Web of Science ®Google Scholar
• Iravani M, Dhat R, Price CM. Methylation of the multi tumor suppressor gene-2 (MTS2, CDKN1, p15INK4B) in childhood acute lymphoblastic leukemia. Oncogene 1997;15:2609–2614.
   PubMed Web of Science ®Google Scholar
• Wong IH, Ng MH, Huang DP, Lee JC. Aberrant p15 promoter methylation in adult and childhood acute leukemias of nearly all morphologic subtypes: potential prognostic implications. Blood 2000;95:1942–1949.
   PubMed Web of Science ®Google Scholar
• Deligezer U, Erten N, Akisik EE, Dalay N. Methylation of the INK4A/ARF locus in blood mononuclear cells. Ann Hematol 2006;85:102–107.
   PubMed Web of Science ®Google Scholar
• O'Keefe C, McDevitt MA, Maciejewski JP. Copy neutral loss of heterozygosity: a novel chromosomal lesion in myeloid malignancies. Blood. 2010;115(14):2731–2739.
   PubMed Web of Science ®Google Scholar
• Batova A, Diccianni MB, Nobori T, et al. Frequent deletion in the methylthioadenosine phosphorylase gene in T-cell acute lymphoblastic leukemia: strategies for enzyme-targeted therapy. Blood 1996;88:3083–3090.
   PubMed Web of Science ®Google Scholar
• Xu N, Li YL, Li X, et al. Correlation between deletion of the CDKN2 gene and tyrosine kinase inhibitor resistance in adult Philadelphiachromosome-positive acute lymphoblastic leukemia. J Hematol Oncol 2016;9:40
   PubMed Web of Science ®Google Scholar
• Chen ZH, Zhang H, Savarese TM. Gene deletion chemoselectivity: codeletion of the genes for p16(INK4), methylthioadenosine phosphorylase, and the a- and b-interferons in human pancreatic cell carcinoma lines and its implications for chemotherapy. Cancer Res 1996;56:1083–1090.
   PubMed Web of Science ®Google Scholar
• Bose P, Simmons GL, Grant S. Cyclin-dependent kinase inhibitor therapy for hematologic malignancies. Expert Opin Investig Drugs 2013;22(6):723–738.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration FDA approves Ibrance for post-menopausal women with advanced breast cancer. Feb 3, 2015. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm432871.htm. Accessed May 22, 2015.
   Google Scholar
• Sherr CJ, Beach D, Shapiro GI. Targeting CDK4 and CDK6: from discovery to therapy. Cancer Discov 2016;6(4):353–367.
   PubMed Web of Science ®Google Scholar
• Wang L, Wang J, Blaser BW, et al. Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia. Blood 2007;110:2075–2083.
   PubMed Web of Science ®Google Scholar
• Dean JL, Thangavel C, McClendon AK, Reed CA, Knudsen ES. Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure. Oncogene 2010;29:4018–4032.
   PubMed Web of Science ®Google Scholar
• Sosman JA, Kittaneh M, Lolkema MPJK, et al. A phase 1b/2 study of LEE011 in combination with binimetinib (MEK162) in patients with NRAS-mutant melanoma: early encouraging clinical activity. J Clin Oncol 2014;32(suppl): abstr 9009.
   Google Scholar
• Vora SR, Juric D, Kim N, et al. CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors. Cancer Cell 2014;26:136–149.
   PubMed Web of Science ®Google Scholar